Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japanese Economy Threatened by “Serious Illness” New Keizai Doyukai Chairman Mr Hasegawa
May 16, 2011
- Actemra Approved for SJIA as Additional Indication in US
May 16, 2011
- Drug Makers to Continue Production through Golden Week
May 16, 2011
- Liovel, Nexium Recommended for Approval
May 16, 2011
- CHMP Gives Positive Opinion for Avastin, Xeloda Combination: Roche
May 16, 2011
- METI to Subsidize Installation of In-house Power Generators
May 16, 2011
- Simponi Recommended for Approval
May 16, 2011
- FDA Issues Complete Response Letter for Aricept Patch: Eisai
May 16, 2011
- Major Drugstore Chains to Hire More New Graduates from Disaster Areas
May 16, 2011
- Kyowa Kirin Files NDA for Anti-CCR4 Antibody KW-0761
May 16, 2011
- Gov't Has Not Yet Considered Postponing Medical, Nursing Fee Revision in 2012: Senior Vice Minister Ohtsuka
May 16, 2011
- Pfizer Allows Special Leave for Volunteers in Disaster Area
May 16, 2011
- Korosho to Create Council on Regulatory Strategies
May 16, 2011
- Discussion Starts to Revise Ethical GL for Genome Analysis
May 16, 2011
- Supreme Court Favors Patent Extension for Takeda's DDS Formulations
May 16, 2011
- Korosho Draws Up Draft Guidance for Risk Management Plans
May 16, 2011
- Kaketsuken, GSK Start PI Trial of New Cell Culture-based Flu Vaccine
May 16, 2011
- Production of Pravastatin Drug Substance to Resume in Sept.: Daiichi Sankyo
May 2, 2011
- Eisai's Halaven for Inoperable Breast Cancer
May 2, 2011
- Lixisenatide Reduces HbA1c in Combination with SU or SU + Metformin
May 2, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…